Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes.

By H. Haller, S. Ito, J. Izzo, A. Januszewicz, S. Katayamá, J. Menne, A. Mimran, T. Rabelink, E. Ritz, L. Ruilope and 2 more. New England Journal of Medicine, 2011

777 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism, Nephrology

View Paper: https://www.semanticscholar.org/paper/f1fddaa387417480a5d6d47e4a85f23fdb657c4a

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. Philippe van de Borne
2. V. Basevi
3. E. Schiffrin
4. H. S. Boudier

In Endocrinology, Diabetes and Metabolism

1. R. Bilous
2. Philippe van de Borne
3. V. Basevi

In Nephrology

1. V. Basevi

Citations in the corpus

• Standards of Medical Care in Diabetes—2012 (2011, background): “In type 2 diabetes with hypertension and normoalbuminuria, RAS inhibition has been demonstrated to delay onset of microalbuminuria in two studies (299,300).”
• KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update. (2012, background): “Studies in normoalbuminuric normotensive patients with type 2 diabetes are fewer but also show no benefit.(91,94) For normoalbuminuric patients with type 2 diabetes and hypertension, or pre-existing CVD, use of ACE-Is with or without diuretics reduces the absolute risk of developing microalbuminuria”
• The 2015 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. (2013, background): “On the other hand, the recent Randomized Olmesartan And Diabetes MicroAlbuminuria Prevention (ROADMAP) study [329] in diabetic patients showed a significant reduction of new-onset microalbuminuria in more intensively treated patients (olmesartan vs.”
• ESH / ESC Guidelines for the management of arterial hypertension (2013, background): “Several RCTs have clearly indicated that RAS blockade is more effective in reducing albuminuria than either placebo or other antihypertensive agents in diabetic nephropathy, non-diabetic nephropathy and patients with CVD,(513,537) and is also effective in preventing incident microalbuminuria.(329,53”
• Standards of Medical Care in Diabetes—2014 (2013, background): “In type 2 diabetes with hypertension and normoalbuminuria, RAS inhibition has been demonstrated to delay onset of elevated albuminuria (416,417).”